reason report
result beat consensu revenu ep
respect driven strong trikafta launch us
despit on-going disrupt trikafta sale increas
prior quarter beat consensu
exceed forecast report sale benefit
pre-purchas ahead covid certain european market
stockpil patient us reason estim
effect contribut approxim revenu
perform thu compani still report signific
beat compar expect partial benefit earli refil
trikafta sale larg driven new patient adopt
convers cf drug manag estim major
elig adult cf patient alreadi trikafta us
uptak curv expect flatten onward total cystic
fibrosi cf product revenu beat consensu
grow sequenti yoy three older
cf drug kalydeco orkambi symdeko miss consensu
sequenti declin due faster convers trikafta symdeko
experienc deeper declin compar kalydeco orkambi
compani increas revenu guidanc
reflect stronger expect trikafta launch
suggest slower growth rest due high trikafta
penetr reach still uncertain effect covid
econom disrupt annual revenu would result
signific beat compar consensu recent estim
may rel weak compar balanc year
reflect continu posit perform signific upsid
gross margin quarter line
expect combin sg
larg line consensu estim overal
oper margin exceed consensu estim
compani suggest profit probabl
wouldnt maintain seem comfort
oper margin go forward combin non-gaap sg
expens guidanc remain unchang slightli
consensu non-gaap tax guidanc reiter
larg in-lin estim consensu consist
prior commun ir team manag expect
minimum disrupt suppli chain manufactur facil
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
 side manag expect major program
remain track although much-anticip phase
antitrypsin defici aatd program paus new
timelin data readout provid call addit
compani evalu multipl earli stage asset variou rare
diseas partner acquisit find hard attribut
much real valu stage grow cash reserv
compani activ like increas manag seem
still focus rel small early-stag asset
strong trikafta launch increas cf forecast price
updat revenu expens forecast base
recent quarter manag guidanc commentari
total revenu forecast increas
modestli decreas chang
primarili base significantli faster revenu trajectori trikafta
partial off-set rapid sale eros three cf drug
particularli longer term revis total revenu forecast
consensu higher oper
expens estim higher lower
base lower sg estim partial
off-set higher cog base chang pro-forma
dilut ep estim increas larg unchang
outer year revis ep estim consensu
larg compar updat multipl
industri peer revis price target versu previous
maintain market perform rate
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access time
reimburs revenu growth tend later expect market expect
vertex cf revenu grow steadili
consensu expect still robust perform compar consensu
expect believ vertex geograph revenu mix continu heavili weight
us due continu resist payer europ dynam
put current consensu medium-term revenu estim risk probabl success
tripl combin market valuat account full expect
valu cf portfolio well risk-adjust opportun compani effort alpha-
antitrypsin defici aatd even posit view new dcf valuat
incorpor sustain oper margin requir consider
disciplin compani reput frugal
incorpor premium price target recogn vertex might one
attract larg cap growth asset sector howev view reason
acquisit premium would price compani nearli like difficult pill
swallow dilution-avers larg compani
revenu nearli full penetr trikafta elig patient
vertex total cf product revenu beat consensu forecast
trikafta first full quarter sale partial benefit earli refil due
disrupt trikafta sale increas sequenti beat consensu
forecast respect fast uptak trikafta suggest high
penetr rate current elig cf patient segment age older least one
mutat growth rate like go slow trikafta re-
gain momentum late earli secur eu approv age expans
us
sale three cf drug declin miss consensu symdeko sale
declin sequenti miss consensu kalydeco q/q
versu consensu orkambi q/q versu consensu declin appear
modest manag suggest doublet still gain growth ou market despit
overal weak due fast convers trikafta us
ep driven higher revenu expens larg in-lin consensu
gross margin larg in-lin consensu estim vertex non-gaap
total oper expens consensu higher
estim non-gaap expens flat compar consensu higher
estim non-gaap sg expens lower consensu
estim compani non-gaap effect tax rate
compar consensu estim non-gaap dilut ep
materi consensu estim
revenu increas guidanc expens tax rate remain
stronger expect trikafta launch annual run-rat almost
vertex manag rais revenu guidanc
manag commentari suggest sever factor contribut strong besid
real demand earli refil believ new revenu guidanc
achiev given littl room growth assum remaind new
revenu guidanc slightli higher latest consensu bracket
forecast non-gaap sg expens guidanc remain unchang
slightli lower consensu lower estim
non-gaap effect tax rate guidanc also unchang in-lin
estim consensu
moder impact develop program
manag expect minim disrupt late-stag cf trial old trikafta studi
fulli enrol expect progress track virtual offic visit home deliveri
enabl vertex continu prepar snda file second half year
follow complet studi tripl combin file ema late last
year current review manag expect delay expect eu
approval/launch late earli previous disclos much-anticip phase
program paus due disrupt new timelin proof-of-concept
biomark readout provid call nevertheless program
current process reiniti patient screen enrol site site accord
manag commentari second program recent complet phase
studi might start phase trial second half year addit vertex recent
initi phase proof-of-concept studi peopl focal segment
glomerulosclerosi fsg despit covid disrupt phase gene-edit program
sickl cell beta thal still open enrol patient howev patient
condit dose paus compani continu expect report
updat data two exist patient potenti new patient data year earli stage
program cell therapi treatment type diabet expect enter clinic
late earli
strong trikafta launch increas cf forecast price
updat revenu expens forecast base recent quarter
manag guidanc commentari total revenu forecast increas
moder decreas chang
primarili base significantli faster revenu trajectori trikafta partial off-set
rapid sale eros three cf drug revis total revenu forecast
consensu higher oper expens estim
higher lower base lower sg estim
partial off-set higher cog base chang pro-forma dilut ep
estim increas larg unchang outer year revis ep
estim consensu larg compar
updat multipl industri peer revis price target versu previous
maintain market perform rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim
discount back year compani cost equiti give valu one year
use averag mid larg cap biotech price-to-revenu multipl sale
appli revenu estim
post-tripl discount back year compani cost equiti give valu
one year lastli dcf valuat given wacc termin cash flow
growth rate give present valu averag three method
current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit trikafta cf drug
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cf tr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
ema approv
end age
older
submit snda us
age
sec gov compani websit present svbl analysi
data
data
phase start
brand chemic
type event
event trial detail
date known
up/down
expect
addit data on-going phase studi
us snda submiss age
start phase studi
start phase studi
ema approv end age
report clinic data peopl two
mutat
svb leerink llc equiti research compani file
million
product sale po adjust
trikafta tripl comb ivacaftor tezacaftor elexacaftor approv
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal earn
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
